{"id":"W4388586208","doi":"10.1093/bjd/ljad429","title":"Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials","year":2023,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; LEO Pharma; Sun Pharma; Eisai; National Institute for Health and Care Research; Manchester Biomedical Research Centre; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Discontinuation; Adverse effect; Psoriasis; Incidence (geometry); Internal medicine; Plaque psoriasis; Gastroenterology; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04737581,0.001462599,0.0071891,0.001489855,0.0004915841,0.002693968,0.001017562,0.002206874,0.002462704],"category_scores_gemma":[0.03903132,0.0009880451,0.02001111,0.00278389,0.0009137588,0.001796349,0.001171517,0.002109905,0.0003426333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008232759,"about_ca_system_score_gemma":0.001780316,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004995082,"about_ca_topic_score_gemma":0.001072032,"domain_scores_codex":[0.9706509,0.0190556,0.004619307,0.002499156,0.002452498,0.0007225226],"domain_scores_gemma":[0.9575965,0.02174514,0.01451136,0.003368241,0.001778541,0.001000225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.4749492,0.0007887405,0.0536276,0.02517821,0.3557152,0.0001679321,0.000214058,0.002932367,0.002593653,0.0002585386,0.004075998,0.07949858],"study_design_scores_gemma":[0.3076724,0.05209342,0.2299258,0.005699187,0.385546,0.0009126524,0.0001655806,0.002238212,0.001575748,0.002035602,0.0119046,0.0002308057],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.4197998,0.5513808,0.007983609,0.001327563,0.0009782118,0.004344489,0.008745163,0.0004063488,0.005034143],"genre_scores_gemma":[0.9333941,0.05063749,0.003359949,0.001711802,0.0007709498,0.003524746,0.005953591,0.0001084129,0.0005389182],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.04737581,"threshold_uncertainty_score":0.2505503,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06127394202515896,"score_gpt":0.3284469304501376,"score_spread":0.2671729884249786,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}